The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic le…

AML/MDSB-ALLT-ALL+1 more

~Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT04318678

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the op…

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

~Estimated

~$10 – $1,125

Immune Oncology Research InstituteNCT05430971

Phase 1

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…

Hematologic MalignancyAMLALL+8 more

~Estimated

~$10 – $7,500

Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770